(Q37783424)

23 August 2017

title

Lipotoxicity and impaired high density lipoprotein-mediated reverse cholesterol transport in chronic kidney disease (English)

1 reference

23 August 2017

Lipotoxicity and Impaired High Density Lipoprotein-Mediated Reverse Cholesterol Transport in Chronic Kidney Disease (English)

1 reference

https://api.crossref.org/works/10.1053/J.JRN.2010.05.010

2 July 2024

1 reference

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20797569

2 July 2024

author name string

Nosratola D. Vaziri

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20797569

2 July 2024

language of work or name

1 reference

1 September 2010

1 reference

full work available at URL

23 August 2017

https://api.elsevier.com/content/article/PII:S105122761000138X?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1053/J.JRN.2010.05.010

https://api.elsevier.com/content/article/PII:S105122761000138X?httpAccept=text/plain

2 July 2024

1 reference

https://api.crossref.org/works/10.1053/J.JRN.2010.05.010

Journal of Renal Nutrition

2 July 2024

published in

1 reference

23 August 2017

volume

20

1 reference

23 August 2017

issue

5 Suppl

1 reference

23 August 2017

page(s)

S35-43

1 reference

Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization

23 August 2017

cites work

2

1 reference

https://api.crossref.org/works/10.1053/J.JRN.2010.05.010

The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia

2 July 2024

3

1 reference

https://api.crossref.org/works/10.1053/J.JRN.2010.05.010

Why is chronic kidney disease the "spoiler" for cardiovascular outcomes?

2 July 2024

4

1 reference

https://api.crossref.org/works/10.1053/J.JRN.2010.05.010

Inflammation in end-stage renal disease: sources, consequences, and therapy

2 July 2024

5

1 reference

https://api.crossref.org/works/10.1053/J.JRN.2010.05.010

Oxidative stress in uremia: nature, mechanisms, and potential consequences

2 July 2024

6

1 reference

https://api.crossref.org/works/10.1053/J.JRN.2010.05.010

Intra-renal angiotensin II/AT1 receptor, oxidative stress, inflammation, and progressive injury in renal mass reduction

2 July 2024

7

1 reference

https://api.crossref.org/works/10.1053/J.JRN.2010.05.010

Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences

2 July 2024

8

1 reference

https://api.crossref.org/works/10.1053/J.JRN.2010.05.010

Down-regulation of tissue lipoprotein lipase expression in experimental chronic renal failure

2 July 2024

9

1 reference

https://api.crossref.org/works/10.1053/J.JRN.2010.05.010

Down-regulation of VLDL receptor expression in chronic experimental renal failure

2 July 2024

11

1 reference

https://api.crossref.org/works/10.1053/J.JRN.2010.05.010

Protein restriction and AST-120 improve lipoprotein lipase and VLDL receptor in focal glomerulosclerosis

2 July 2024

12

1 reference

https://api.crossref.org/works/10.1053/J.JRN.2010.05.010

Down-regulation of hepatic LDL receptor-related protein (LRP) in chronic renal failure

2 July 2024

13

1 reference

https://api.crossref.org/works/10.1053/J.JRN.2010.05.010

Impaired antioxidant activity of high-density lipoprotein in chronic kidney disease

2 July 2024

14

1 reference

https://api.crossref.org/works/10.1053/J.JRN.2010.05.010

Down-regulation of hepatic lecithin:cholesterol acyltransferase gene expression in chronic renal failure

2 July 2024

15

1 reference

https://api.crossref.org/works/10.1053/J.JRN.2010.05.010

Upregulation of acyl-CoA: cholesterol acyltransferase in chronic renal failure

2 July 2024

16

1 reference

https://api.crossref.org/works/10.1053/J.JRN.2010.05.010

ACAT inhibition reverses LCAT deficiency and improves plasma HDL in chronic renal failure

2 July 2024

17

1 reference

https://api.crossref.org/works/10.1053/J.JRN.2010.05.010

The induction of macrophage foam cell formation by chylomicron remnants.

2 July 2024

18

1 reference

https://api.crossref.org/works/10.1053/J.JRN.2010.05.010

Effects of native and modified low-density lipoproteins on monocyte recruitment in atherosclerosis

2 July 2024

19

1 reference

https://api.crossref.org/works/10.1053/J.JRN.2010.05.010

Inflammation and atherosclerosis

2 July 2024

20

1 reference

https://api.crossref.org/works/10.1053/J.JRN.2010.05.010

The molecular basis of vulnerable plaque: potential therapeutic role for immunomodulation

2 July 2024

21

1 reference

https://api.crossref.org/works/10.1053/J.JRN.2010.05.010

Myeloperoxidase: an inflammatory enzyme for generating dysfunctional high density lipoprotein.

2 July 2024

22

1 reference

https://api.crossref.org/works/10.1053/J.JRN.2010.05.010

Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment

2 July 2024

23

1 reference

https://api.crossref.org/works/10.1053/J.JRN.2010.05.010

Endothelial protection by high-density lipoproteins: from bench to bedside

2 July 2024

24

1 reference

https://api.crossref.org/works/10.1053/J.JRN.2010.05.010

High-density lipoprotein metabolism: potential therapeutic targets

2 July 2024

25

1 reference

https://api.crossref.org/works/10.1053/J.JRN.2010.05.010

Atheroprotective effects of HDL: beyond reverse cholesterol transport.

2 July 2024

26

1 reference

https://api.crossref.org/works/10.1053/J.JRN.2010.05.010

Lipid and apolipoprotein profiles of uremic dyslipoproteinemia--relation to renal function and dialysis

2 July 2024

27

1 reference

https://api.crossref.org/works/10.1053/J.JRN.2010.05.010

Hepatic HDL receptor, SR-B1 and Apo A-I expression in chronic renal failure

2 July 2024

28

1 reference

https://api.crossref.org/works/10.1053/J.JRN.2010.05.010

Effect of serum subfractions from peritoneal dialysis patients on Hep-G2 cell apolipoprotein A-I and B metabolism

2 July 2024

30

1 reference

https://api.crossref.org/works/10.1053/J.JRN.2010.05.010

Serum albumin is a significant intermediate in cholesterol transfer between cells and lipoproteins

2 July 2024

31

1 reference

https://api.crossref.org/works/10.1053/J.JRN.2010.05.010

Impaired metabolism of high density lipoprotein in uremic patients

2 July 2024

32

1 reference

https://api.crossref.org/works/10.1053/J.JRN.2010.05.010

Cell surface adenylate kinase activity regulates the F(1)-ATPase/P2Y (13)-mediated HDL endocytosis pathway on human hepatocytes.

2 July 2024

33

1 reference

https://api.crossref.org/works/10.1053/J.JRN.2010.05.010

Cholesteryl ester transfer protein as a protective factor against vascular disease in hemodialysis patients

2 July 2024

34

1 reference

https://api.crossref.org/works/10.1053/J.JRN.2010.05.010

Hepatic lipase mutation may reduce vascular disease prevalence in hemodialysis patients with high CETP levels

2 July 2024

35

1 reference

https://api.crossref.org/works/10.1053/J.JRN.2010.05.010

Plasma phospholipid transfer protein, cholesteryl ester transfer protein and lecithin:cholesterol acyltransferase in end-stage renal disease (ESRD).

2 July 2024

36

1 reference

https://api.crossref.org/works/10.1053/J.JRN.2010.05.010

Molecular mechanisms of lipid disorders in nephrotic syndrome

2 July 2024

37

1 reference

https://api.crossref.org/works/10.1053/J.JRN.2010.05.010

Abnormalities in hepatic lipase in chronic renal failure: role of excess parathyroid hormone

2 July 2024

38

1 reference

https://api.crossref.org/works/10.1053/J.JRN.2010.05.010

Identification of scavenger receptor SR-BI as a high density lipoprotein receptor

2 July 2024

39

1 reference

https://api.crossref.org/works/10.1053/J.JRN.2010.05.010

Down-regulation of hepatic high-density lipoprotein receptor, SR-B1, in nephrotic syndrome

2 July 2024

40

1 reference

https://api.crossref.org/works/10.1053/J.JRN.2010.05.010

Ectopic beta-chain of ATP synthase is an apolipoprotein A-I receptor in hepatic HDL endocytosis

2 July 2024

41

1 reference

https://api.crossref.org/works/10.1053/J.JRN.2010.05.010

Understanding changes in high density lipoproteins during the acute phase response.

2 July 2024

42

1 reference

https://api.crossref.org/works/10.1053/J.JRN.2010.05.010

Mechanisms of disease: proatherogenic HDL--an evolving field

2 July 2024

43

1 reference

https://api.crossref.org/works/10.1053/J.JRN.2010.05.010

In vitro stimulation of HDL anti-inflammatory activity and inhibition of LDL pro-inflammatory activity in the plasma of patients with end-stage renal disease by an apoA-1 mimetic peptide

2 July 2024

44

1 reference

https://api.crossref.org/works/10.1053/J.JRN.2010.05.010

The paradox of dysfunctional high-density lipoprotein

2 July 2024

45

1 reference

https://api.crossref.org/works/10.1053/J.JRN.2010.05.010

HDL-inflammatory index correlates with poor outcome in hemodialysis patients

2 July 2024

46

1 reference

https://api.crossref.org/works/10.1053/J.JRN.2010.05.010

Cellular lipid metabolism and the role of lipids in progressive renal disease

2 July 2024

47

1 reference

https://api.crossref.org/works/10.1053/J.JRN.2010.05.010

Lipotoxicity: when tissues overeat

2 July 2024

48

1 reference

https://api.crossref.org/works/10.1053/J.JRN.2010.05.010

Experimental glomerulopathy alters renal cortical cholesterol, SR-B1, ABCA1, and HMG CoA reductase expression

2 July 2024

49

1 reference

https://api.crossref.org/works/10.1053/J.JRN.2010.05.010

Multiple metabolic hits converge on CD36 as novel mediator of tubular epithelial apoptosis in diabetic nephropathy

2 July 2024

50

1 reference

https://api.crossref.org/works/10.1053/J.JRN.2010.05.010

Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease

2 July 2024

51

1 reference

https://api.crossref.org/works/10.1053/J.JRN.2010.05.010

Acute tubular injury causes dysregulation of cellular cholesterol transport proteins

2 July 2024

52

1 reference

https://api.crossref.org/works/10.1053/J.JRN.2010.05.010

Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes

2 July 2024

53

1 reference

https://api.crossref.org/works/10.1053/J.JRN.2010.05.010

Renal mass reduction results in accumulation of lipids and dysregulation of lipid regulatory proteins in the remnant kidney

2 July 2024

54

1 reference

https://api.crossref.org/works/10.1053/J.JRN.2010.05.010

Reverse cholesterol transport pathway in experimental chronic renal failure

2 July 2024

55

1 reference

https://api.crossref.org/works/10.1053/J.JRN.2010.05.010

Atherosclerosis. the road ahead

2 July 2024

56

1 reference

https://api.crossref.org/works/10.1053/J.JRN.2010.05.010

Antisense to LOX-1 inhibits oxidized LDL-mediated upregulation of monocyte chemoattractant protein-1 and monocyte adhesion to human coronary artery endothelial cells

2 July 2024

57

1 reference

https://api.crossref.org/works/10.1053/J.JRN.2010.05.010

The role of the kidney in lipid metabolism

2 July 2024

58

1 reference

https://api.crossref.org/works/10.1053/J.JRN.2010.05.010

The molecular interactions between filtered proteins and proximal tubular cells in proteinuria.

2 July 2024

59

1 reference

https://api.crossref.org/works/10.1053/J.JRN.2010.05.010

The ACAT inhibitor avasimibe reduces macrophages and matrix metalloproteinase expression in atherosclerotic lesions of hypercholesterolemic rabbits

2 July 2024

60

1 reference

https://api.crossref.org/works/10.1053/J.JRN.2010.05.010

Carbohydrate response element binding protein directly promotes lipogenic enzyme gene transcription

2 July 2024

61

1 reference

https://api.crossref.org/works/10.1053/J.JRN.2010.05.010

SREBP-1, a membrane-bound transcription factor released by sterol-regulated proteolysis

2 July 2024

62

1 reference

https://api.crossref.org/works/10.1053/J.JRN.2010.05.010

Peroxisome proliferator-activated receptor family and its relationship to renal complications of the metabolic syndrome

2 July 2024

63

1 reference

https://api.crossref.org/works/10.1053/J.JRN.2010.05.010

ATP-Binding cassette cholesterol transporters and cardiovascular disease

2 July 2024

64

1 reference

https://api.crossref.org/works/10.1053/J.JRN.2010.05.010

Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis

2 July 2024

65

1 reference

https://api.crossref.org/works/10.1053/J.JRN.2010.05.010

Rosuvastatin and cardiovascular events in patients undergoing hemodialysis

2 July 2024

66

1 reference

https://api.crossref.org/works/10.1053/J.JRN.2010.05.010

Effect of atorvastatin on inflammation and outcome in patients with type 2 diabetes mellitus on hemodialysis

2 July 2024

67

1 reference

https://api.crossref.org/works/10.1053/J.JRN.2010.05.010

Antioxidant therapy does not ameliorate oxidative stress and inflammation in patients with end-stage renal disease.

2 July 2024

68

1 reference

https://api.crossref.org/works/10.1053/J.JRN.2010.05.010

Regression of atherosclerosis induced by liver-directed gene transfer of apolipoprotein A-I in mice

2 July 2024

69

1 reference

https://api.crossref.org/works/10.1053/J.JRN.2010.05.010

Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial

2 July 2024

70

1 reference

https://api.crossref.org/works/10.1053/J.JRN.2010.05.010

Oral D-4F causes formation of pre-beta high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice

2 July 2024

71

1 reference

https://api.crossref.org/works/10.1053/J.JRN.2010.05.010

Differential effects of apolipoprotein A-I-mimetic peptide on evolving and established atherosclerosis in apolipoprotein E-null mice.

2 July 2024

72

1 reference

https://api.crossref.org/works/10.1053/J.JRN.2010.05.010

D-4F and statins synergize to render HDL antiinflammatory in mice and monkeys and cause lesion regression in old apolipoprotein E-null mice

2 July 2024

73

1 reference

https://api.crossref.org/works/10.1053/J.JRN.2010.05.010

Apolipoprotein A-I mimetic peptides: potential role in atherosclerosis management

2 July 2024

74

1 reference

https://api.crossref.org/works/10.1053/J.JRN.2010.05.010

2 July 2024

Identifiers

1 reference

23 August 2017

1 reference